243 related articles for article (PubMed ID: 21902586)
21. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
22. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
[TBL] [Abstract][Full Text] [Related]
23. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
24. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.
Catani MV; Corasaniti MT; Navarra M; Nisticò G; Finazzi-Agrò A; Melino G
J Neurochem; 2000 Jun; 74(6):2373-9. PubMed ID: 10820198
[TBL] [Abstract][Full Text] [Related]
25. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
26. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
27. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
28. [Conclusions and perspectives. Maraviroc].
Alcamí J
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
[TBL] [Abstract][Full Text] [Related]
29. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Moore JP; Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):118-24. PubMed ID: 19339950
[TBL] [Abstract][Full Text] [Related]
30. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
31. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
32. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
[TBL] [Abstract][Full Text] [Related]
33. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
[TBL] [Abstract][Full Text] [Related]
34. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
[TBL] [Abstract][Full Text] [Related]
35. Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.
Kramer VG; Varsaneux O; Oliviera M; Colby-Germinario SP; Mesplède T; Wainberg MA
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):7-14. PubMed ID: 24872133
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
38. In vitro inhibitory effect of maraviroc on the association of the simian immunodeficiency virus envelope glycoprotein with CCR5.
Giraudy I; Ovejero CA; Affranchino JL; González SA
Virus Genes; 2021 Feb; 57(1):106-110. PubMed ID: 33400102
[TBL] [Abstract][Full Text] [Related]
39. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
40. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
